US FDA approves Jazz Pharmaceuticals’ Modeyso to treat recurrent H3 K27M-mutant diffuse midline glioma

Jazz Pharmaceuticals plc, a global biopharma company, announced that the US Food and Drug Administration (FDA) has granted accelerated approval for Modeyso (dordaviprone) for the treatment of adult and

To access the full article, please log in or subscribe.